A leading biopharmaceutical company in the discovery and development of RNAi therapeutics, Sirnaomics Ltd. (the “Company” or “Sirnaomics,” stock code: 2257.HK) announced today that it will present the most recent advancements on GalAheadTM, a GalNAc-RNAi therapeutic platform, and its pipeline programmes at two industry conferences in Boston: the RNA Leaders USA Congress and 18th Drug Discovery Innovation Programme.

The 18th Drug Discovery Innovation Programme will be held October 26–27 at The Westin Copley Place, while the RNA Leaders USA Congress will be held October 18–19 at The Colonnade Hotel.
Sirnaomics is an RNA therapeutics biopharmaceutical company that focuses on the research and development of novel medications for conditions with unmet medical needs and significant market potential. Its product candidates are currently in preclinical and clinical stages. In addition to being the first firm to achieve successful Phase IIa clinical outcomes in oncology for an RNAi treatment for its flagship product, STP705, Sirnaomics is also the first clinical-stage RNA therapeutics company to have a significant presence in both China and the United States.

Source: Prnewswire